Vera Therapeutics
VERA
214 hedge funds and large institutions have $3.75B invested in Vera Therapeutics in 2025 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 79 increasing their positions, 59 reducing their positions, and 18 closing their positions.
290% more call options, than puts
Call options by funds: $48.6M | Put options by funds: $12.5M
244% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 18
98% more capital invested
Capital invested by funds: $1.89B → $3.75B (+$1.86B)
34% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 59
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
22% more funds holding
Funds holding: 175 → 214 (+39)
13.82% more ownership
Funds ownership: 101.95% → 115.77% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$100M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$63.8M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$60.3M |
| 4 |
Holocene Advisors
New York
|
+$46.4M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$41.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$39.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$29.8M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$23M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$21.1M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$16.4M |
VERA Hedge Fund Activity: Q4 2025 in Review
214 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q4 2025, worth a combined $3.75B — up 98% from $1.89B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new VERA positions and 18 closed out — a net gain of 44 holders — while 79 added to existing stakes and 59 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $100M. The largest seller was Tang Capital Management, exiting entirely with an estimated $39.2M sold.
- 214 institutional investors held Vera Therapeutics (VERA) as of Q4 2025, up from 175 in Q3 2025.
- Funds reported $3.75B of Vera Therapeutics stock for Q4 2025, up 98% quarter-over-quarter.
- 62 funds opened new Vera Therapeutics positions in Q4 2025 and 18 closed out, a net change of +44 holders.
- The largest Vera Therapeutics buyer in Q4 2025 was Deep Track Capital, an estimated $100M added.
- The largest Vera Therapeutics seller in Q4 2025 was Tang Capital Management, an estimated $39.2M sold.
Based on aggregated 13F filings for Q4 2025.